|
|
???tair.name??? >
???browser.page.title.author???
|
"peng cm"???jsp.browse.items-by-author.description???
Showing items 1-9 of 9 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國家衛生研究院 |
2024-03-25 |
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer
|
Tang, CY;Yang, SH;Li, CP;Su, YY;Chiu, SC;Bai, LY;Shan, YS;Chen, LT;Chuang, SC;Chan, DC;Yen, CJ;Peng, CM;Chiu, TJ;Chen, YY;Chen, JS;Chiang, NJ;Chou, WC |
| 國家衛生研究院 |
2023-02-05 |
Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer
|
Su, YY;Chiang, NJ;Yang, YH;Yen, CJ;Bai, LY;Chiu, CF;Chuang, SC;Yang, SH;Chou, WC;Chen, JS;Chiu, TJ;Chen, YY;Chan, DC;Peng, CM;Chiu, SC;Li, CP;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2022-11-15 |
The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinoma
|
Chiang, NJ;Shan, YS;Li, CP;Yang, SH;Su, YY;Chiu, SC;Bai, LY;Chuang, SC;Chan, DC;Yen, CJ;Peng, CM;Chiu, TJ;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2022-09-15 |
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Chen, YY;Hsueh, SW;Yang, SH;Chiu, SC;Chiang, NJ;Chiu, TJ;Li, CP;Bai, LY;Chiu, CF;Chuang, SC;Shan, YS;Chan, DCA;Chen, LT;Yen, CJ;Peng, CM;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2022-06-22 |
Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: A real-world multicenter study
|
Su, YY;Chiang, NJ;Li, CP;Yen, CJ;Yang, SH;Chou, WC;Chen, JS;Chiu, TJ;Chen, YY;Chuang, SC;Bai, LY;Chiu, CF;Peng, CM;Chan, DC;Chiu, SC;Yang, YH;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2022-04-15 |
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan
|
Yang, SH;Chiang, NJ;Chiu, SC;Chou, WC;Bai, LY;Li, CP;Su, YY;Chiu, TJ;Chuang, SC;Peng, CM;Chan, DC;Chen, JS;Yen, CJ;Chen, YY;Chiu, CF;Chen, LT;Shan, YS |
| 國家衛生研究院 |
2022-02-19 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Chiu, TJ;Yang, SH;Chiu, SC;Hsueh, SW;Chiang, NJ;Li, CP;Bai, LY;Cheng, FM;Chuang, SC;Shan, YS;Chan, DC;Chen, LT;Yen, CJ;Peng, CM;Su, YY;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2021-11-20 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
|
Chiu, TJ;Su, YY;Yang, SH;Li, CP;Bai, LY;Chiang, NJ;Chuang, SC;Shan, YS;Chan, DC;Chen, LT;Yen, CJ;Peng, CM;Chen, YY;Chen, JS;Chou, WC |
| 中山醫學大學 |
2021 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study
|
Chiu, TJ; Su, YY; Yang, SH; Li, CP; Bai, LY; Chiang, NJ; Chuang, SC; Shan, YS; Chan, DC; Chen, LT; Yen, CJ; Peng, CM; Chen, YY; Chen, JS; Chou, WC |
Showing items 1-9 of 9 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
